Skip to content

Study · Non-randomized trial · n = 555 · 2023

2 results

Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.

Yao J, Zhang M, Zhang X, Zhang J

Diabetes therapy : research, treatment and education of diabetes and related disorders21 Feb 2023

PMID36809495 (opens in a new tab)PMCIDPMC10064411 (opens in a new tab)DOI10.1007/s13300-023-01369-6 (opens in a new tab)PepBankPUB-36809495
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In the pooled Asian diabetes analysis including lixisenatide recipients, no severe hypoglycemia was reported.

    In plain wordsIn the Asian diabetes analysis including lixisenatide recipients, researchers reported no severe hypoglycemia.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedSevere hypoglycemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No severe hypoglycemia was reported.
    3 context sentences
    Summary · context
    This analysis investigated the efficacy and safety of add-on lixisenatide by disease duration in Asian people with type 2 diabetes inadequately controlled with basal insulin ± oral antidiabetic drugs.
    Summary · context
    Data for Asian participants in the GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies were pooled and categorized by diabetes duration: < 10 years (group 1), 10 to < 15 years (group 2), and ≥ 15 years (group 3).
    Summary · context
    Efficacy and safety of lixisenatide versus placebo were evaluated by subgroup.
  2. 02HumanObservational studyEfficacy outcome

    In Asian people with diabetes, lixisenatide treatment effects did not differ significantly across duration subgroups for HbA1c, FPG, PPG, PPG excursion, weight, BMI or HbA1c target response (interaction P > 0.1).

    In plain wordsIn Asian people with diabetes, glucose and body-composition treatment effects of lixisenatide did not differ significantly across disease-duration subgroups.

    Peptide
    Lixisenatide
    Outcome
    No significant changeTreatment-effect heterogeneity across glycemic and body-composition outcomes
    Study

    n = 555

    Comparator
    Other diabetes-duration subgroups
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant differences in treatment effect between the duration subgroups were observed for the changes from baseline to 24 weeks in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial glucose (PPG), PPG excursion, body weight or body mass index, or the proportion of particip…
    3 context sentences
    Summary · context
    This analysis investigated the efficacy and safety of add-on lixisenatide by disease duration in Asian people with type 2 diabetes inadequately controlled with basal insulin ± oral antidiabetic drugs.
    Summary · context
    Data for Asian participants in the GetGoal-Duo 1, GetGoal-L, and GetGoal-L-C studies were pooled and categorized by diabetes duration: < 10 years (group 1), 10 to < 15 years (group 2), and ≥ 15 years (group 3).
    Summary · context
    Efficacy and safety of lixisenatide versus placebo were evaluated by subgroup.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT01632163

Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin

Sanofin = 447Oct 2012 to May 2015

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 15 Jun 2015
CompletedPhase 3Results postedNCT00975286

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Sanofin = 446Oct 2009 to Aug 2011

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 11 Oct 2016
CompletedPhase 3Results postedNCT00715624

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Sanofin = 496Jul 2008 to Feb 2011

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 28 Nov 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.